Cord reinfusion in type 1 diabetes (CoRD) pilot study
Overview:
Australian researchers at The Children’s Hospital at Westmead, in a
world first clinical trial (CoRD Study), are investigating the
potential to prevent or delay the onset of type 1 diabetes (T1D) in
high risk children using a child’s own (autologous) cord blood. This
pilot study funded by Cell Care and is open to parents across
Australia who have stored (or planning to store) their child’s own
(autologous) cord blood. The trial aims to recruit 400-600
participants in the initial screening phase to identify children at
high risk of developing T1D. A total of 20 children identified at
high risk will be offered reinfusion of their cord blood.
Participants will be monitored and followed for up to 3
years.
Location: Sydney, Australia
Trial design: Pilot study
Status: Open - currently recruiting
Find out more
Cord blood infusion for type 1 diabetes mellitus (T1DM)
Overview:
Researchers in Bavaria, Germany, aim to recruit 23 children from the
age of 1 with T1D mellitus to undergo infusion of autologous (their
own) cord blood in an attempt to regenerate the insulin producing
cells in the pancreas and improve blood glucose control. As
secondary goals, the investigators aim to track the migration of
transfused cord blood stem cells and study the potential changes in
metabolism and immune function leading to islet regeneration.
Location: Bavaria, Germany
Trial design: Safety and efficacy
Status: Active – not recruiting
Find out more